ข่าวประชาสัมพันธ์ Ingenol Mebutate

Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis

Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 months An analysis of long-term clearance rates of actinic keratosis (AK) lesions after treatment with ingenol mebutate (Picato(R)) gel is today published in the Journal of the American Medical Association (JAMA) Dermatology,[1] formerly known as the Archives of Dermatology. (Photo: http://photos.prnewswire.com/prnh/20130221/595427 ) Previously, the pooled results of the four phase III trials of ingenol

Four Phase 3 Efficacy and Safety Studies of Ingenol Mebutate, an Investigational Treatment for Actinic Keratosis, Presented at World Congress of Dermatology

- Ingenol Mebutate is an Investigational Two-to-Three Day Topical Treatment for Precancerous Skin Disease Clinical data from four Phase 3...